Kestra Private Wealth Services’s Chemomab Therapeutics CMMB Stock Holding History

Kestra Private Wealth Services’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Hold	61,710	–	–	﹤0.01%	1743
2026 Q1	$96.9K	Buy	61,710 +10,000	+19%	+$17.1K	﹤0.01%	1693
2025 Q4	$85.3K	Buy	+51,710	New	+$137K	﹤0.01%	1664
2025 Q3	–	Sell	-7,810	Closed	-$36.2K	–	1688
2025 Q2	$36.2K	Hold	7,810	–	–	﹤0.01%	1584
2025 Q1	$34.1K	Hold	7,810	–	–	﹤0.01%	1480
2024 Q4	$56.5K	Hold	7,810	–	–	﹤0.01%	1384
2024 Q3	$49K	Hold	7,810	–	–	﹤0.01%	1336
2024 Q2	$28.5K	Hold	7,810	–	–	﹤0.01%	1326
2024 Q1	$24.3K	Hold	7,810	–	–	﹤0.01%	1280
2023 Q4	$15.9K	Hold	7,810	–	–	﹤0.01%	1202
2023 Q3	$28K	Hold	7,810	–	–	﹤0.01%	1145
2023 Q2	$41.1K	Hold	7,810	–	–	﹤0.01%	1049
2023 Q1	$49.7K	Hold	7,810	–	–	﹤0.01%	1012
2022 Q4	$100K	Buy	+7,810	New	+$67.4K	0.01%	848

Other funds holding CMMB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

PIP

Philadelphia Investment Partners Voorhees, New Jersey $161M AUM

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Private Wealth Services's CMMB Position: Q2 2026 in Review

Kestra Private Wealth Services held its Chemomab Therapeutics (CMMB) position steady in Q2 2026 at 61,710 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Kestra Private Wealth Services first reported a position in CMMB in Q4 2022 and has held it in 14 quarters since. The position peaked at $100K in Q4 2022. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

Kestra Private Wealth Services held 61,710 shares of Chemomab Therapeutics worth $100K as of Q2 2026.
Kestra Private Wealth Services left its Chemomab Therapeutics share count unchanged in Q2 2026.
Chemomab Therapeutics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1743 holding.
Kestra Private Wealth Services first reported a position in Chemomab Therapeutics in Q4 2022 and has held it in 14 quarters since.
Kestra Private Wealth Services's Chemomab Therapeutics position peaked at $100K in Q4 2022.
13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.